Evidence map›Paper›PMID 34116813›Full record

Trial reportJournal of substance abuse treatment2021

Utilizing patient perception of group treatment in exploring medication adherence, social support, and quality of life outcomes in people who inject drugs with hepatitis C.

Kerry A Howard, Lior Rennert, Irene Pericot-Valverde, Moonseong Heo, Brianna L Norton, Matthew J Akiyama, Linda Agyemang, Alain H Litwin

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kerry A HowardDepartment of Public Health Sciences, Clemson University, Clemson, SC, USA.
Lior RennertDepartment of Public Health Sciences, Clemson University, Clemson, SC, USA.
Irene Pericot-ValverdeClemson University School of Health Research, Clemson, SC, USA; Department of Medicine, Prisma Health-Upstate, Greenville, SC, USA.
Moonseong HeoDepartment of Public Health Sciences, Clemson University, Clemson, SC, USA.
Brianna L NortonAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Matthew J AkiyamaAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Linda AgyemangAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Alain H LitwinClemson University School of Health Research, Clemson, SC, USA; Department of Medicine, Prisma Health-Upstate, Greenville, SC, USA; University of South Carolina School of Medicine Greenville, Greenville, SC, USA. Electronic address: Alain.Litwin@prismahealth.org.

Funding

Intensive Models of HCV Care for Injection Drug UsersR01DA034086 · NIDA · CLEMSON UNIVERSITY · PI LITWIN, ALAIN HARRIS · 2012 to 2016
$3.7M
Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject DrugsDP2DA053730 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2021 to 2021
$2.5M
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants LivingR00DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2020 to 2022
$747k
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants Living with Hepatitis C-The HCV-ACCELERATE TrialK99DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI AKIYAMA, MATTHEW · 2017 to 2018
$369k
NIDA NIH HHS DP2 DA053730NIDA NIH HHS K99 DA043011NIDA NIH HHS R00 DA043011NIDA NIH HHS R01 DA034086
6 · The paper itself

Abstract

People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV). Group treatment is a practical option for addressing barriers to treatment in this population. Prior research on group treatment has resulted in mixed conclusions about its effectiveness in addressing barriers to treatment. A patient's perception of the group environment may help to explain this variability. This study sought to explore the association between indicators of group treatment environment and improved outcomes in HCV-infected PWID. This secondary analysis of a randomized controlled trial exploring different models of treatment for HCV in a PWID population consisted of 42 participants randomized to the group treatment branch of the trial. Independent variables consisted of group sessions attended and group climate constructs of engagement, conflict, and avoidance. Dependent variables consisted of medication adherence, social support, and health-related quality of life. The study implemented generalized estimating equations to assess associations with the outcomes at the end of treatment. Factors indicative of group treatment environment were related to medication adherence and other barriers to health for HCV-infected PWID: social support and health-related quality of life. Perceptions of conflict or avoidance were associated with worse outcomes, while increased session attendance was generally associated with better outcomes. The study attests to the importance of examining group environment factors during treatment interventions. Although preliminary, the study provides specific indicators of treatment success for HCV-infected PWID and practical implications to improve patients' health outcomes and better tailor treatment to the patient.

Indexed as

Hepatitis CPharmaceutical PreparationsSubstance Abuse, IntravenousAntiviral AgentsHepacivirusHumansMedication AdherencePerceptionQuality of LifeSocial SupportAntiviral AgentsPharmaceutical PreparationsGroup climateGroup treatmentHepatitis C virusPeople who inject drugs

Identifiers

PMID34116813
PMCPMC8714173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.